
Find a clinical trial
Please use one or more of the field below to begin your search.
All clinical trials
-
Protocol number: 00000370
An Observational Study on the role of Hemophagocytosis in Patients with Anemia and Hemolytic Anemia
-
Protocol number: 015-00-E7080-G000-321
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) plus Lenvatinib (E7080/MK-7902) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma (LEAP-015)
-
Protocol number: 01AT21-MET
A Phase 1/2 Open-Label, Dose-Escalation and Dose Expansion Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIS) In Adult Participants With MET-Driven NSCLC
-
Protocol number: 10445
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
-
Protocol number: 1150-101/PXL262601
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
-
Protocol number: 14605760-MODEL-CRC
MicroOrganoSphereTM (MOS) Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)
-
Protocol number: 1705018187-NCT04843566
Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complications
-
Protocol number: 18H-MC-BDCV
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Daily Injections
-
Protocol number: 2013-0496
A cross-over pilot study of the effect of amiloride compared to triamterene on proteinuria in patients with proteinuric kidney disease
-
Protocol number: 2014-0755
Identifying children with diabetes type 1 at high risk for cardiovascular disease
-
Protocol number: 2014-1041
Circulating Free DNA Molecular Tumor Response to Definitive Treatment
-
Protocol number: 2017-0440
An Open Label, Phase I study to evaluate the impact of low doses of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in HuntingtonÂ’s Disease
-
Protocol number: 2017-0478
STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction
-
Protocol number: 2017-0700-NCT03685461
Intra- and Post-Operative Measures of Auditory Function
-
Protocol number: 2017-0838/GR412607
Optimizing Bilateral and Single-Sided Deafness Cochlear Implants for Functioning in Complex Auditory Environments
-
Protocol number: 2017-0961
MRI evaluation of recurrent disk herniation without post-contrast imaging using 3D T2 SPACE
-
Protocol number: 2017-1041-NCT03104517
CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence
-
Protocol number: 2017-1316
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double Blinded, Safety Study (BRAVOS)
-
Protocol number: 2018-0191
Investigation of the Effects of Radioactive Iodine on the Salivary Glands
-
Protocol number: 2018-0439
A Randomized Trial of Proactive Outreach and Streamlined Genetic Education in BRCA Families
-
Protocol number: 2018-0979
A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device
-
Protocol number: 2018-1092
A Retrospective Chart Review and analysis of oncologic patients undergoing curative or palliative treatments within the MedStar Georegetown University Hospital Interventional Radiology Department
-
Protocol number: 2018-242
Outcomes Evaluation of the Medial Femoral Trochlea Flap for Reconstruction of the Scaphoid and Lunate
-
Protocol number: 2020-1406
A feasibility (pilot) study of simultaneous detection of minimal residual disease and chimerism by Next Generation Sequencing analysis of circulating cell-free DNA/RNA for patients undergoing allogeneic hematopoietic stem cell transplantation in the treatment of a myeloid malignancy
-
Protocol number: 208090
A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed
-
Protocol number: 209035
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482
-
Protocol number: 221AD304
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)
-
Protocol number: 718-CIH-201
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington s Disease
-
Protocol number: 718-CIH-202
A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants with Huntington's Disease
-
Protocol number: A011801-COMPASSHER-NCT04457596
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
-
Protocol number: A021806-NCT04340141
A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
-
Protocol number: A022104-JANUS
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
-
Protocol number: A031702-NCT03866382
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
-
Protocol number: A031704-PDIGREE-NCT0379316
A031704, PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr [PDIGREE]
-
Protocol number: A031803-NCT04164082
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-
Protocol number: A031902-CASPAR
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
-
Protocol number: A041703-NCT03739814
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
-
Protocol number: A081801-NCT04267848
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
-
Protocol number: A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
-
Protocol number: A151216-ALCHEMIST-NCT02194738
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
-
Protocol number: A211801-BRCA-P-NCT04711109
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
-
Protocol number: A221805
DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY
-
Protocol number: AALL1732-NCT03959085
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
-
Protocol number: AAML1831-NCT04293562
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
-
Protocol number: AAML18P1-NCT03817398
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
-
Protocol number: ABBVIEM20-339
Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients
-
Protocol number: ABOLISH
INTERNATIONAL, MULTICENTRE, OBSERVATIONAL, PROSPECTIVE, LONGITUDINAL STUDY TO ASSESS THE EFFECTIVENESS OF ABOBONT-A INJECTIONS FOR ADULT LOWER LIMB SPASTICITY IN A REAL LIFE COHORT (ABOLISH)
-
Protocol number: ACT17209
A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia
-
Protocol number: ACURATE-NCT03735667
Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR
-
Protocol number: ADAP-008-NCT04545333
Real World Observational Study using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The Watch Registry
-
Protocol number: ADMIRE-BWI201910
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System
-
Protocol number: ADNI3-NCT02854033
AlzheimerÂ’s Disease Neuroimaging Initiative 3 (ADNI3)
-
Protocol number: AFFINITY-NCT03222973
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
-
Protocol number: AFT-50-NCT04486352
A Phase IB/II Multi-Cohort Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
-
Protocol number: AGCT1531-NCT03067181
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
-
Protocol number: AGCT1532-NCT02582697
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
-
Protocol number: AGT-HC168
Phase I Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants with HIV that is Well-Controlled on Antiretroviral Therapy
-
Protocol number: AGT103-T-LTFU
A Long-Term Follow-Up Study of Participants Treated with the LentiviralBased Genetically Modified, Autologous Cell Product, AGT103-T
-
Protocol number: AHEAD3-45
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer s Disease and Intermediate Amyloid (A3 Trial)
-
Protocol number: AHEP1531-NCT03533582
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
-
Protocol number: AIBERRY-STUDY00003473
Developing an A.I. Platform to Detect Depression Predict depression at higher degree of accuracy Implement the Aiberry platform in a live environment
-
Protocol number: AIMPOWER-NCT04191330
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
-
Protocol number: AIMSS
Improving Adherence to Aromatase Inhibitor therapy in early-stage breast cancer by early physiatry consultation to decrease AIMSS
-
Protocol number: ALCOHOLICHEPATITIS
Outcomes of Alcoholic Hepatitis and Alcohol Cirrhosis Patients after Liver Transplant
-
Protocol number: ALIGN-AR-NCT04415047
A Study to Assess Safety and Probable Benefit of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation (AR)
-
Protocol number: ALLIANCE-NCT05172960
Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve
-
Protocol number: ALLO-316-101-NCT04696731
A PHASE 1 MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF ALLO-316 FOLLOWING ALLO-647 CONTAINING CONDITIONING REGIMEN IN SUBJECTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (ccRCC)
-
Protocol number: ALTE1631-NCT03223753
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer
-
Protocol number: ALTE2031-NCT04089358
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
-
Protocol number: AMG423-SHAH-NCT02929329
Registrational Study to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)
-
Protocol number: AML-PROSPECTIVE-STUDY00000298
A Pilot Study to Evaluate Physical Function and Fatigue in Patients with Acute Myeloid Leukemia Single Center Prospective Cohort Study
-
Protocol number: AML-RETROSPECTIVE- STUDY00001361
A center-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia (AML)
-
Protocol number: AMPLATZER-PFO-NCT03309332
AMPLATZER PFO Occluder Post Approval Study (PFO PAS)
-
Protocol number: ANHL1931-NCT04759586
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
-
Protocol number: ANX-WAIHA-01
A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia
-
Protocol number: ANX005-HD-001
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington s Disease
-
Protocol number: ANX005-WAIHA-02
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of- Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia
-
Protocol number: APEC14B1
APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
-
Protocol number: APEC1621SC-NCT03155620
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
Protocol number: APOL-1
Integrating a Culturally Competent APOL1 Genetic Testing Program into Living Donor Evaluation
-
Protocol number: APOLLO-NCT03242642
Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial
-
Protocol number: APOLLO-NCT03615235
APOL1 LONG-TERM KIDNEY TRANSPLANTATION OUTCOMES NETWORK (APOLLO)
-
Protocol number: ARCADIA-NCT03192215-NRH
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)
-
Protocol number: AREN1921-NCT04322318
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors(DAWT)and Relapsed Favorable Histology Wilms Tumors(FHWT)
-
Protocol number: ARGX-113-2004
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
-
Protocol number: ARGX-113-2005
A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
-
Protocol number: ARIES-HM3-NCT04069156
Antiplatelet Removal and HemocompatIbility EventS with the HeartMate 3 Pump
-
Protocol number: ARST1431-NCT02567435
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
-
Protocol number: ASPIRE-NCT03907046-GUMC
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
-
Protocol number: ATA129-EBV-302-NCT03394365
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy
-
Protocol number: ATN-106
A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery
-
Protocol number: ATRC-101-A01
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies
-
Protocol number: ATX-MAP-001-NCT03517917
Prospective collection of donor tissue and whole blood or leukapheresis product from patients with solid tumors to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT).
-
Protocol number: AURORAUS-NCT03737695
AURORA US: PROSPECTIVE BIOSPECIMEN REPOSITORY IN METASTATIC BREAST CANCER
-
Protocol number: AVA-ITP-401
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim
-
Protocol number: B-60-NCT04622319
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY (T-DXd vs. T-DM1 in high-risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy)
-
Protocol number: BAN2401-G000-301
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease.
-
Protocol number: BBI-20201001-NCT04278144
Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2- Expressing Solid Tumors
-
Protocol number: BHV3500-203
BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen
-
Protocol number: BI1305-0014
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
-
Protocol number: BIODESIX
A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules
-
Protocol number: BMTCTN1903-NCT04975698
Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
-
Protocol number: BOLT-NCT05003843
BOLT: A Prospective, Multicenter Study of Patients with Deep Vein Thrombosis to Evaluate the Safety and Efficacy of the Indigo® Aspiration System
-
Protocol number: BOND-003
A Phase 3 Study of CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
-
Protocol number: BP-LVAD
Blood Pressure and Outcomes in Contemporary Left Ventricular Assist Device Recipients
-
Protocol number: BQ5-NCT05044507
The efficacy of a frequency-tuned electromagnetic field treatment in facilitating the recovery of subacute ischemic stroke patients a pivotal study
-
Protocol number: BURN-RADIATION
A Systems Biology Approach to Radiation Biodosimetry and the Host- Environment Interaction: Applications to Mass Casualty Triage in the Polytrauma Patient.
-
Protocol number: C-14
CORRECT-MRD II: SECOND COLORECTAL CANCER CLINICAL VALIDATION STUDY TO PREDICT RECURRENCE USING A CIRCULATING TUMOR DNA ASSAY TO DETECT MINIMAL RESIDUAL DISEASE
-
Protocol number: C-800-23-NCT05529316
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
-
Protocol number: C3441052-NCT04821622
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
Protocol number: C4221015-NCT04607421
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
-
Protocol number: C4671034
A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised
-
Protocol number: CA224-098-NCT05002569
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
-
Protocol number: CA42481
A Phase II, Open-Label, Randomized, Multicenter Study To Investigate the Pharmacodynamics, Pharmacokinetics, Safety and efficacy of 8mg/kg or 4mg/kg Intravenous Tocilizumab in Patients with moderate to severe COVID-19 Pneumonia
-
Protocol number: CAAA617C12301
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
-
Protocol number: CAD
Hand arterial calcification as a predictor for subclinical coronary artery disease using coronary artery calcium scoring.
-
Protocol number: CAD-DECISIONAID
Shared Decision Making in the Prevention and Management of Cardiovascular Disease
-
Protocol number: CAPTIVA-NCT05047172
CAPTIVA is a two-stage Phase III trial randomizing subjects with stroke attributed to 70-99% intracranial atherosclerotic stenosis (sICAS) to: 1) ticagrelor + aspirin 2) low dose rivaroxaban + aspirin 3) clopidogrel + aspirin The primary goal of the trial is to determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death). The first stage of the trial is concluded by an interim safety analysis intended to identify an excess of parenchymal intracerebral hemorrhage (ICH) or non-ICH major hemorrhage with ticagrelor + aspirin or low dose rivaroxaban + aspirin that could lead to an early termination of one or both of those arms. The second stage of the trial will determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) that progress to stage 2 are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death). An exploratory aim is to estimate the impact of CYP2C19 loss-of-function (LOF) carrier status on any benefit that the ticagrelor or low dose rivaroxaban arms may have in lowering the primary endpoint compared with the clopidogrel arm.
-
Protocol number: CARDIAMP-NCT02438306
Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients With Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
-
Protocol number: CARDIOL-100-102
Impact of CardiolRxTM on Myocardial Recovery in Acute Myocarditis
-
Protocol number: CARDUS-HANDHELD
Handheld Cardiac Ultrasound in Resident Assessment of Left Ventricular Ejection Fraction in Outpatients
-
Protocol number: CARILLON-NCT03142152
Assessment of the Carillon® Mitral Contour System® in Treating Functional Mitral Regurgitation Associated With Heart Failure - The CARILLON Trial
-
Protocol number: CATALYST-NCT04226547
Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants
-
Protocol number: CERCLAGEEFS-NCT03929913
NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty early feasibility study
-
Protocol number: CGT9486-21-301-PEAK
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors (PEAK)
-
Protocol number: CGX1321-101-NCT02675946
A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors
-
Protocol number: CHAMPION-AF
WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation
-
Protocol number: CHIMES-NCT04377555
AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB
-
Protocol number: CLASP-IID-NCT03706833
Edwards PASCAL TrAnScatheter Mitral Valve RePair System Pivotal Clinical Trial (CLASP IID): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR).
-
Protocol number: CLR1806-NCT03655236
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF K0706 IN SUBJECTS WITH EARLY PARKINSON S DISEASE
-
Protocol number: COE-002-1116
Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Retrospective Outcomes-Associated Database
-
Protocol number: COLOPLAST-INTIBIA
A Prospective, Randomized Clinical Trial Evaluating INTIBIA, an Investigational Implantable Tibial Nerve Stimulator, Through 24-Months.
-
Protocol number: COMBINE1-4591
A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti-diabetic drugs, in participants withtype 2 diabetes inadequately controlled with daily basal insulin. COMBINE 1
-
Protocol number: COMBINE3-4593
A 52-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. COMBINE 3
-
Protocol number: COMPARTMENTSYNDROME
Non-Invasive Observational Study of Extremity Compartment Syndrome Using Philips Ultrasound Shear Wave Elastography and Micro-vascular Flow Imaging
-
Protocol number: CONFIDES-NCT04935177
A Phase III Randomized Controlled Trial to Evaluate 1-Year eGFR in Highly Sensitized (cPRA Greater than or equal to 99.9%) Deceased Donor Kidney Transplant Recipients, Following Imlifidase-Inactivation of HLA Antibodies Prior to Transplantation
-
Protocol number: CONNECT-HF-NCT03035474
CARE OPTIMIZATION THROUGH PATIENT AND HOSPITAL ENGAGEMENT CLINICAL TRIAL FOR HEART FAILURE CONNECT-HF
-
Protocol number: CONVERGEPAS
Post-Approval Study Protocol For Hybrid Convergent Of Epicardial RF Ablation And Endocardial Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
-
Protocol number: CORCINCH-HF
Randomized Clinical Evaluation of the AccuCinch® Ventricular Repair System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
-
Protocol number: COREVNS-NCT03529045
Comprehensive Outcomes Registry in Subjects with Epilspsy Treated with Vagus Nerve Stimulation Therapy
-
Protocol number: CORMATRIX-NCT02397668
CORMATRIX® COR™ TRICUSPID ECM® VALVE REPLACEMENT SAFETY AND EARLY FEASIBILITY STUDY
-
Protocol number: COS-AUL-NCT05546190
Assessing benefits from a long-acting toxin (IPN10200) from the patient perspective in adult upper limb (AUL) spasticity
-
Protocol number: COVID-ARC-19-NCT04401449
Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)
-
Protocol number: COVID-CALYPSO
COVID-19 associated Lymphopenia Pathogenesis Study in Blood
-
Protocol number: COVID-REP0321
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19. A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial.
-
Protocol number: CYTOKINETICS-CY6022
An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM)
-
Protocol number: CYTOKINETICS-CY6031
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK-3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
-
Protocol number: D7310C00001-NCT04590963
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
-
Protocol number: D8850C00006
Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 Years
-
Protocol number: D910PC00001-VOLGA
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
-
Protocol number: D926PC00001-TROPION-02
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) VersusInvestigator s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)
-
Protocol number: DB-1303-O-1001-NCT05150691
A Phase 1/2a Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors
-
Protocol number: DCCOHORT-COVID
Measuring the Impact of COVID-19 among and Urban Cohort of PLWH in Washington DC.
-
Protocol number: DCL-16-001-NCT02952508
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-I) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
-
Protocol number: DCM-CMR-STUDY
Dilated Cardiomyopathy (DCM) Research Project Sub-study: Advanced Procedures Sub-Study
-
Protocol number: DCP-002
Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate among Racially and Ethnically Diverse Populations
-
Protocol number: DEFINE-GPS
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting
-
Protocol number: DEXTERITY-CIP0217
DEXTERITY-AFP: Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
-
Protocol number: DEXTERITY-CIP0218
DEXTERITY-SCI: Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
-
Protocol number: DFU-GSH
Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers
-
Protocol number: DFU-WHC
Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers
-
Protocol number: DIRECTION-NCT04936542
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity
-
Protocol number: DIS-DMTMS
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
-
Protocol number: DISCOMS-NCT03073600
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
-
Protocol number: DISRUPTPAD-BTKII
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries
-
Protocol number: DLS-NCTNA
Collection of Bio-fluid Samples from Pregnant Women for the Evaluation of Biomarkers for Preeclampsia
-
Protocol number: DRESSINGCOMPARRISON
A Comparison of Split-thickness Skin Graft Primary Dressings When Used with Autologous Skin Cell Suspension.
-
Protocol number: DUET-CD
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease”
-
Protocol number: DUET-UC
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis.
-
Protocol number: DURECTAH
A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
-
Protocol number: EA1151-TMIST-NCT03233191
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA 1151
-
Protocol number: EA2174-NCT03604991
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
-
Protocol number: EA2182-NCT04166318
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
-
Protocol number: EA2185-PANCREATIC-NCT04239573
Comparing Two Methods to Follow Patients With Pancreatic Cysts
-
Protocol number: EA2186-GIANT
A Randomized Phase II Study of Gemcitabine and Nab Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
-
Protocol number: EA3191
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
-
Protocol number: EA3202
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
-
Protocol number: EA6141-NCT02339571
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
-
Protocol number: EA6174-NCT03712605
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
-
Protocol number: EA6192
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
-
Protocol number: EA8184
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
-
Protocol number: EA8192
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
-
Protocol number: EA8212-BRIDGE
EA8212: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
-
Protocol number: EARLYTAVR-NCT03042104
Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: EARLY TAVR trial
-
Protocol number: EASESBS2EXT-NCT03905707
A Double-Blind Phase 3 Extension Trial Assessing the Long-Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel
-
Protocol number: EEG-ENDO
Investigation of pre-operative electroencephalogram (EEG) based central sensitivity measurements on surgical outcomes for patients undergoing operative laparoscopy for endometriosis diagnosis and treatment.
-
Protocol number: EKO
Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting
-
Protocol number: ELEGANCE-REGISTRY
ELEGANCE Drug-ELuting REGistry: ReAl-World Treatment of LesioNs in the Peripheral VasCulaturE
-
Protocol number: EMPACT-MI
EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction
-
Protocol number: EMPAKIDNEY-NCT03594110
A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
-
Protocol number: ENCIRCLE-NCT04153292
The ENCIRCLE Trial SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss
-
Protocol number: ENLIGHTEN-NCT04140305
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
-
Protocol number: EQU-202
A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
-
Protocol number: ES201601-NCTNA
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer
-
Protocol number: ESR-18-13870
A Phase II Trial of Durvalumab (MEDI4736) in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
-
Protocol number: ETCTN10166-NCT03600701
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
-
Protocol number: ETCTN10334
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
-
Protocol number: EV-ICD-CAS
ExtraVascular Implantable Cardiac Defibrillator (EV ICD) Continued Access Study
-
Protocol number: EVAULT
Long-term outcomes following vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study (eVAULT)
-
Protocol number: EXT00000206-PRELUDE
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
-
Protocol number: EXTEND-001
Thoraflex Hybrid and Relay Extension Post-Approval Study (EXTEND)
-
Protocol number: FAMI
Functional Arm Use After Musculoskeletal Injury as a Measure of Recovery
-
Protocol number: FARAPULSE-ADVENT-NCT04612244
A Prospective Randomized Pivotal Trial of the FARAPULSE Pulsed Field Ablation System Compared with Standard of Care Ablation in Patients with Paroxysmal Atrial Fibrillation
-
Protocol number: FAST
Functional Arm Use After Stroke (FAST) as a Measure of Motor Recovery After Stroke
-
Protocol number: FAST-ULTRASOUND
Abdominal FAST imaging of Adult Trauma Patients to Build an Annotated Ultrasound Image Library for Development of Automated Ultrasound Image Acquisition and Interpretation Algorithms.
-
Protocol number: FENTREPID
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
-
Protocol number: FEVAR-NCT04526938
Clinical Outcomes, Radiation Dosage, and Quality of Life in Patients Treated with Fenestrated Stent Grafts for Complex Thoracoabdominal and Abdominal Aortic Aneurysms, and Thoracoabdominal Aortic Aneurysms secondary to Aortic Dissections
-
Protocol number: FFP
Identification of Mechanisms Underlying the Effects of Plasma Inclusive Resuscitation in Major Thermal Injury on Hemostasis and Vascular Homeostasis
-
Protocol number: FGCL-3019-091
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
-
Protocol number: FREEDOM--NCT03995901
A 5-year, randomized, controlled, multi-center study to assess the safety and efficacy of FCR001 cell-based therapy relative to tacrolimus and mycophenolate mofetil in de novo living donor renal transplant recipients and safety in FCR001 donors
-
Protocol number: GA43360
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclerosis
-
Protocol number: GEMINI-1-NCT04410978
A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 1)
-
Protocol number: GENERATION1-NCT02565511
A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
-
Protocol number: GN42272
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
-
Protocol number: GO42216
A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS-LIVER)
-
Protocol number: GO43104
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZOLIZUMAB
-
Protocol number: GORE-VIAFORT-NCT05409976
Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction with or without Combined Iliofemoral Obstruction
-
Protocol number: GORETAG-NCT02777528
Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta
-
Protocol number: GORETAMBE-NCT03728985
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
-
Protocol number: GP-88
Serum GP-88 Levels in Metastatic Breast Cancer patients: A Prospective Blood Sampling Trial
-
Protocol number: GRAIL-02-PATHFINDER-2
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
-
Protocol number: GS-US-200-4334
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV
-
Protocol number: GS-US-425-6143
GS-US-425-6143 - A Phase 1b Randomized, Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GS-8588 in People with HIV-1 who are Virologically Suppressed on Antiretroviral Therapy
-
Protocol number: GS-US-576-6220
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
-
Protocol number: GU16-260-NCT03117309
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
-
Protocol number: HA-PEEK
A Multi-center, Patient Outcome Registry for a Hydroxyapatite infused PEEK Interbody Fusion Device
-
Protocol number: HBVFB
Impact of Recent Immigration on Delays in Care Delivery among Foreign-Born with Chronic Hepatitis B Infection
-
Protocol number: HEAL-IST
Hybrid Epicardial and Endocardial Sinus-Node SpAring AbLation Therapy for Inappropriate Sinus Tachycardia
-
Protocol number: HEM-PWRV1US
HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A
-
Protocol number: HEP3
Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy
-
Protocol number: HEPE-NCT02190253
Seroprevalence of Hepatitis E in Organ Transplant subjects
-
Protocol number: HI-PEITHO
A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.
-
Protocol number: HIALIVER-NCT03734393
HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
-
Protocol number: HP-00081403-NCT03652428
Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer
-
Protocol number: HSG001
Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™)
-
Protocol number: I-SPY2-NCT01042379
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
-
Protocol number: I5T-MC-AACI
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
-
Protocol number: I8H-MC-BDCX
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with Type 2 Diabetes
-
Protocol number: I8H-MC-BDCY
A Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple Daily Injection Therapy
-
Protocol number: IBSAMUMH-NCT03094416
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
-
Protocol number: IMMUKNOW
Utility of ImmuKnow, an Immune Cell Function Assay, in a Cardiac Sarcoid Population
-
Protocol number: IMPROVE-NCT04221815
IMPact on Revascularization Outcomes of intraVascular ultrasound guided treatment of complex lesions and Economic impact (IMPROVE)
-
Protocol number: INCB18424-369
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
-
Protocol number: INF-04-NCT04094818
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis (SEPSIS-SHIELD)
-
Protocol number: INS-415
ARISE -A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
-
Protocol number: INS-416
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
-
Protocol number: INS1007-301
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis The ASPEN Study
-
Protocol number: INSIGHT012
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
-
Protocol number: INSMED312-NCT02628600
An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
-
Protocol number: INTEGRA2017-0908
The Relationship Between Bacterial Load and the Clinical Outcomes for Integra in Operative Wounds
-
Protocol number: INVIVO-SKMICRO
In vivo evaluation of aging-dependent skin microvascular function in HIV infected individuals
-
Protocol number: IO-FDG-MONITOR
Pilot Study of Serial 18F-FDG Uptake Assessment for Prediction of Anti-PD-1 Therapy Response and Progression Free Survival in Patients with Advanced Melanoma
-
Protocol number: ION-682884-CS2
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
-
Protocol number: IOV-COM-202-NCT03645928
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
-
Protocol number: ISPYCOVID
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
-
Protocol number: ISS-20207331-NCT05199311
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma
-
Protocol number: ISS-59074-PEMBRO-LENV
A phase II trial of combination therapy of pembrolizumab and Lenvatinib in patients with locally advanced or metastatic cervical cancer
-
Protocol number: J2W-MC-PYAB
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness
-
Protocol number: J2X-MC-PYAH
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)
-
Protocol number: JAGUAR-CP-0017
ObJective Analysis to GaUge EVAR Outcomes Through Randomization
-
Protocol number: JENAVALVE-AR-NCT02732704
JenaValve Pericardial TAVR Aortic Regurgitation Study
-
Protocol number: JENAVALVE-AS-NCT02732691
JenaValve Pericardial TAVR System Aortic Stenosis Study
-
Protocol number: JEWEL-IDE-NCT05201495
A Clinical Evaluation of the Jewel™ P‐WCD in Subjects at High Risk for Sudden Cardiac Arrest
-
Protocol number: JTX-8064-101
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
-
Protocol number: KETOROLAC
Effect of Ketorolac Administration on Postoperative Narcotic Utilization and Union Rates in Great Toe Arthrodesis
-
Protocol number: KEYNOTE-992-NCT04241185
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
-
Protocol number: KRASG12C
A retrospective cohort study of patient characteristics and treatment outcomes among patients with KRAS G12C mutated non-small cell lung cancer in the Academic Thoracic Oncology Medical Investigator s Consortium (ATOMIC)
-
Protocol number: KT413-DL-101-NCT05233033
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
-
Protocol number: KUPFER-BM-3680
Collection of blood and bone marrow from patients with genetic blood and bone marrow disease
-
Protocol number: L3Y-MC-JPEF-05169567
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
-
Protocol number: LATHAMFUND
Interpreting Glycemic Control in People with Type 2 Diabetes and Chronic Kidney Disease
-
Protocol number: LAU-20-01
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY OF THE EFFICACY AND SAFETY OF LAU-7b IN THE TREATMENT OFADULT HOSPITALIZED PATIENTS WITH COVID-19 DISEASE
-
Protocol number: LEAAPS-CP-2021-05
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
-
Protocol number: LEANORA
evaLuation of variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA study
-
Protocol number: LEARN-NCT02488720
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
-
Protocol number: LIMB-ISCHEMIA
Prospective Study Evaluating the Effect of Skin Pigmentation on Clinical Exam for Determination of Limb Ischemia in Patients with Digital Injuries
-
Protocol number: LIST
A prospective pilot study to assess for histologic changes on vulvar biopsies in postmenopausal women with Lichen Sclerosus treated with Fractionated CO2 Laser therapy
-
Protocol number: LITERACY
Limited Health Literacy in Patients with Rotator Cuff Tears: Risk Factors and Outcome Effects
-
Protocol number: LOWRISKTAVR-NCT02628899
Feasibilty of Transcatheter Aortic Valve Replacement in Low-Risk Patients with Symptomatic, Severe Aortic Stenosis
-
Protocol number: LPX-641-001
A multicenter observational study for Immune-phenotyping and ex-vivo evaluation of the likelihood of response to an experimental tolerance restoration therapy in subjects diagnosed with multiple sclerosis (MS).
-
Protocol number: LUNGFEATURES
Use of Point of Care Ultrasound to Collect Lung Images in Subjects with lower respiratory symptoms
-
Protocol number: LUNGULTRASOUND-SMOKE
Use of Philips Lumify Point-of-Care Handheld Ultrasound to Identify Smoke Inhalation Lung Injury.
-
Protocol number: M19-148
A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
-
Protocol number: M20-098
Advanced Parkinson's Disease: An Open-Label Extension of Studies M15-736 and M20-339 Evaluating the Safety and Tolerability of ABBV-951
-
Protocol number: M21-459
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm Study to Assess the Safety and Efficacy of a Single Treatment of BOTOX®, Followed by an Optional Open-Label Treatment with BOTOX®, in Female Subjects with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
-
Protocol number: M6-CPAS-NCT04122248
M6-C™ Artificial Cervical Disc IDE Post-Approval Study
-
Protocol number: M602011069
Prospective, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label period to investigate the efficacy and safety of NT 201 in the unilateral and bilateral treatment of essential tremor of the upper limb
-
Protocol number: MAPLE-NCT04793360
Molecular Assessment and Profiling of Liver Transplant Recipients
-
Protocol number: MARCH
Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis
-
Protocol number: MATCH-STUDY
Measurements of AV Access Blood Flow with the Alio Medical Remote Monitoring System to Determine Maturation Status and Patency in ESRD Patients
-
Protocol number: MCLA-128-CL01-NCT02912949
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
-
Protocol number: MEDIWOUNDNEXT-NCT04040660
Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries
-
Protocol number: MERCK-MK-8591
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
-
Protocol number: MITRAL2-NCT04408430
The safety and effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra valve with Commander delivery system in patients with symptomatic severe calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.
-
Protocol number: MK-3475-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
-
Protocol number: MK-3475-U01-NCT04165798
A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
-
Protocol number: MK-6482-011
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
-
Protocol number: MK-6482-022-NCT05239728
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)
-
Protocol number: MK-6482-024
A multicenter, open-label, Randomized Phase 1/2 Study of belzutifan in combination with palbociclib vs belzutifan monotherapy in participants with advanced RCC
-
Protocol number: MK-8591A-017
A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy
-
Protocol number: MK-8591A-019
A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL
-
Protocol number: MK3475-365-NCT02861573
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
-
Protocol number: MK3475-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
-
Protocol number: MK3475-U01-NCT04165798
Master: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
-
Protocol number: MK7339-013
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
-
Protocol number: MK7684A-006
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiation followed by MK- 7684A Versus Concurrent Chemoradiation followed by Durvalumab in Participants with Unresectable, Locally-advanced, Stage III NSCLC Lung
-
Protocol number: ML42919
A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab with Atezolizumab plus Bevacizumab in Previously-Treated Advanced Non- squamous NSCLC
-
Protocol number: ML43975-NCT05482516
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers with Microscopic Residual Disease
-
Protocol number: MNA-3521-012
AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)
-
Protocol number: MOR208C310-NCT04824092
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
-
Protocol number: MRDPANC
Minimal Residual Disease in Resected Pancreatic Adenocarcinoma, a Pilot Study (MRD PANC)
-
Protocol number: MRX-503-NCT04185363
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)
-
Protocol number: MRX-EAP
An Expanded-Access Program for Maralixibat in Patients with Cholestatic Pruritis Associated with Alagile Syndrome
-
Protocol number: NAPOLI-2-NCT04005339
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
-
Protocol number: NATURALHISTORY-NCT00009243
Evaluation, Pathogenesis and Treatment of Patients with or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)
-
Protocol number: NBI-98854-HD3006
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington Disease
-
Protocol number: NCT01574053
Enroll-HD: A Prospective Registry Study in a Global HuntingtonÂ’s Disease Cohort A CHDI Foundation Project
-
Protocol number: NCT01892345
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)
-
Protocol number: NCT02242487
A 12-Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in ParkinsonÂ’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)
-
Protocol number: NCT02397096
A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
-
Protocol number: NCT02403674
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
-
Protocol number: NCT02901717
MDA 2013-0039:A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infect
-
Protocol number: NCT03209401-2017-0085
Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies
-
Protocol number: NEROFE
Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
-
Protocol number: NEUROCOGNITION
Rate of Neurocognitive Decline in Adults with Sickle Cell Disease: an institutional Study
-
Protocol number: NGM707-IO-101
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
-
Protocol number: NIC-NCT02720445
Long Term Nicotine Treatment of Mild Cognitive Impairment
-
Protocol number: NLY01PD1-NCT04154072
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage ParkinsonÂ’s Disease
-
Protocol number: NN9535-4984
Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study
-
Protocol number: NOD
Clinical Investigation of Inflammatory Bowel Diseases, Intestinal Failure and Transplantation
-
Protocol number: NODE-301-NCT03464019
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
-
Protocol number: NOPRODLUC0002
Collection of human-derived, healthy and disease-specific biological samples for the development and control of laboratory assays, procedures and general research.
-
Protocol number: NRG-BN009
PHASE III TRIAL OF SALVAGE STEREOTACTIC RADIOSURGERY (SRS) OR SRS + HIPPOCAMPALAVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR FIRST OR SECOND DISTANT BRAIN RELAPSE AFTER UPFRONT SRS WITH BRAIN METASTASIS VELOCITY ≥4 BRAIN METASTASES/YEAR
-
Protocol number: NRG-BR007-NCT04852887
A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE </= 18 BREAST CANCER
-
Protocol number: NRG-CC003
RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER
-
Protocol number: NRG-CC009
PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY (SRS) VERSUS HIPPOCAMPAL-AVOIDANT WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR 10 OR FEWER BRAIN METASTASES FROM SMALL CELL LUNG CANCER
-
Protocol number: NRG-GI-005-04068103
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
-
Protocol number: NRG-GI008-NCT05174169
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
-
Protocol number: NTX20201
A Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring below the Distal Border of the Brachial Plexus Requiring Surgical Repair.
-
Protocol number: NVL-520-01
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
-
Protocol number: NVL-655-01
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
-
Protocol number: OHAND-NCT04035005
A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
-
Protocol number: ON-Q-PUMP
The impact of the continuous infusion of intraperitoneal analgesics on postoperative pain after minimally invasive hysterectomy: a randomized controlled trial
-
Protocol number: ONC-392-001
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
-
Protocol number: ONO-4059-09-NCT04947319
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
-
Protocol number: ONWARD
A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with noninsulinanti-diabetic treatment, in insulin naïve subjects with type 2 diabetes.
-
Protocol number: ORGANOXMETRAPAS-NCT0552632
OrganOx metra® New Enrollment Post-Approval Study Protocol
-
Protocol number: ORTHOSPACE-NCT02493660
A Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears
-
Protocol number: PACER
A Phase II Study of electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement
-
Protocol number: PACES
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG (PACeS)
-
Protocol number: PACIFIC4-FSQ
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
-
Protocol number: PALBODCIS-NCT03535506
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
-
Protocol number: PANCDX
Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)
-
Protocol number: PARADIGHM-NCT01922440
A Registry for Patients With Chronic Hypoparathyroidism (PARADIGHM)
-
Protocol number: PAYA-ART-THERAPY
Art Therapy in hematology/oncology/bone marrow transplant clinics for Pediatric, Adolescent, and Young Adult patients: A pilot multi-site mixed methods observational study
-
Protocol number: PERFORMANCEII-NCT04201132
Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integrated eMbolic filter, and A Novel Carotid stEnt II
-
Protocol number: PERSONA-TINIDIUM
A Post-Market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data using the Persona Ti-Nidium Total Knee System and Instrumentation
-
Protocol number: PEX-002
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation
-
Protocol number: PGX-ACT
Pharmacogenomics (PGx) Applied to Chronic pain Treatment in primary care (PGx-ACT)
-
Protocol number: PIVOTAL-IDE
Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation Using the Cryoballoon for Treatment of Persistent Atrial Fibrillation (PIVoTAL) - IDE Trial
-
Protocol number: PL101-HD301
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
-
Protocol number: POLYNOVO-NCT04090424
A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries.
-
Protocol number: PR200-104
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)
-
Protocol number: PRECISE
Perfusion imaging to identify posterior circulation candidates for thrombectomy
-
Protocol number: PRELUDE-NCT02768402
Percutaneous Mitral Valve Replacement EvaLuation Utilizing IDE Early Feasibility Study (PRELUDE)
-
Protocol number: PRO2020-0280
A Multi-Center Phase 1b/2 Study of Daratumumab with Pomalidomide and Dexamethasone in Combination with All-Transretinoic Acid in Patients with Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens
-
Protocol number: PRO2020-0369
A Phase 2B study of selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide in patients with multiple myeloma relapsing on current therapy
-
Protocol number: PRO2021-1263
Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma
-
Protocol number: PROACTIVEHF-NCT04089059
A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients
-
Protocol number: PROGRESS-NCT03777059
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)
-
Protocol number: PSR-APV
Aortic, Peripheral & Venous (APV) Product Surveillance Registry Platform Base
-
Protocol number: PTK0796-NTM-20203
A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
-
Protocol number: R10933-10987-COV-2176
Regeneron / Prophylactic Protocol / R10933-10987-COV-2176
-
Protocol number: RAGE-2021
RAGE inhibition to decrease cancer therapy related cardio toxicity in women with non-metastatic breast cancer
-
Protocol number: RAPA-501-ALLO
Donation of Blood Lymphocytes for Manufacturing of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for Post-Intubation Stage 3 COVID-19 Disease
-
Protocol number: REFINE-ALS-NCT04259255
Radicava®/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
-
Protocol number: REPLACE-CV-MVT-601-056
Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
-
Protocol number: RESTORE-NCT02586623
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
-
Protocol number: RETRO
A2/A2B to B Transplantation Reduces Disparities in Transplant Access While Maintaining Current Levels of Graft and Patient Survival
-
Protocol number: RETROCLK
Retrospective study to analyze patient and transplant outcomes in recipients of combined Liver and Kidney Transplant (CLK) at the Medstar Georgetown University Hospital (MGUH)
-
Protocol number: RISE-NCT04729751
Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome
-
Protocol number: ROADSTER3-NCT05365490
POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in STANDARD RISK PATIENTS with SIGNIFICANT CAROTID ARTERY DISEASE The ROADSTER 3 Study
-
Protocol number: ROCHE-ATPO
Sample Collection for Clinical Performance Evaluation of Elecsys Anti-TPO II
-
Protocol number: ROCHE-NATURALHISTORY
A multi-site, prospective, longitudinal, cohort study measuring cerebrospinal fluid mutant-huntingtin protein in patients with Huntington's Disease
-
Protocol number: RPNI
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Randomized, Prospective Study
-
Protocol number: RT234-PAH-CL202
A Phase 2b, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
-
Protocol number: S1925-NCT04269902
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
-
Protocol number: S1931-PROBE
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
-
Protocol number: S2015
Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
-
Protocol number: S2472
An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphereTM followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphereTM Alone For Hepatocellular Carcinoma (HCC)
-
Protocol number: SAG2424
Psychometric Validation Study for the HuntingtonÂ’s Disease Everyday Functioning (Hi-DEF) Scale
-
Protocol number: SANOFIACT16970
A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension
-
Protocol number: SAVISCOUT
SAVI SCOUT® System for Excision of nonpalpable breast lesions: Single institutional study regarding experiences, lessons learned & comparisons to needle localization
-
Protocol number: SBS-NCT01990040
A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
-
Protocol number: SCONE
Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder ( SCONE Clinical Study )
-
Protocol number: SECURE
A ProSpective, MulticEnter, Concurrently Controlled Clinical Study of Chondro-Gide® ArticUlar Cartilage CoveR for the Treatment of Large Chondral Lesions in the KnEe (SECURE)
-
Protocol number: SELECT-NCT03574597
Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
-
Protocol number: SELUTION-SLR-NCT04280029
SELUTION SLR™ 014 ISR: A Prospective Randomized Single Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Subjects with In-stent Restenosis
-
Protocol number: SGNTUC-025-NCT04539938
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
-
Protocol number: SJS-TENS
Comprehensive Genomic Analysis of Adverse Vaccine and Cutaneous Adverse Drug Reactions
-
Protocol number: SMA-CHART-REVIEW-NCT99999999
Emerging Real-World Use of Nusinersen in Adult Patients with Spinal Muscular Atrophy (SMA) in the US: A Multi-Site Chart Review Study
-
Protocol number: SMART-TRIAL
SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial)
-
Protocol number: SOS-AMI
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
-
Protocol number: SPINALSINGULARITY-NCT04059159
ES-NIH-01: Clinical Evaluation of the Connected Catheter Wireless Urinary Prosthesis for Management of chronic Urinary Retention
-
Protocol number: SPLIT
Prospective Observational Study to Assess Outcomes in Pediatric Liver Transplant Recipients
-
Protocol number: STABLE-NCT03585491
Shoulder Instability Trial comparing arthroscopic stabilization benefits compared with Latarjet procedure evaluation (STABLE)
-
Protocol number: STAR-T-NCT04976530
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T): A Prospective, Multi-center, Double-blind, Randomized, Study to Evaluate Reduction in Postoperative Bleeding by Removal of Ticagrelor with the Intraoperative use of the DrugSorb-ATR Device in Patients Undergoing on-pump Cardiothoracic Surgery within Two Days of Ticagrelor Discontinuation
-
Protocol number: STEP-1
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study
-
Protocol number: STRATAECR
Scarring in Stratagraft-treated vs. autograft-treated burn wounds: a clinical and histological investigation
-
Protocol number: STRATASOMA
A Phase 1/2a, Controlled, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of StrataGraft Skin Tissue Overlay of Meshed Autograft (SOMA) in Treatment of Full-Thickness Thermal Burns
-
Protocol number: STRUCTURE-NCT04294004
A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)
-
Protocol number: STUDY00000017
A randomized, double blind, placebo-controlled study to evaluate the impact of Bosutinib on safety, tolerability, biomarkers and clinical outcomes in Dementia with Lewy Bodies (DLB)
-
Protocol number: STUDY00000122
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)
-
Protocol number: STUDY00000266
A randomized, double blind, placebo-controlled study to evaluate the impact of K0706 on safety, tolerability, pharmacokinetics and pharmacodynamics and clinical outcomes in Dementia with Lewy Bodies (DLB).
-
Protocol number: STUDY00000501
Chronic Stress, QOL, and Physical Activity among Breast Cancer Survivors
-
Protocol number: STUDY00000805
Biomarkers to Evaluate Immune Related Adverse Events (irAEs) Due to Treatment with Immune Checkpoint Inhibitors (ICIs)
-
Protocol number: STUDY00001007
Peer Support For Young Adult Women With High Breast Cancer Risk
-
Protocol number: STUDY00001137
Parent Communication Study IV: Improving Genetic Counseling for BRCA+ Mothers
-
Protocol number: STUDY00001487-TBCRC047
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
-
Protocol number: STUDY00001840-NCT04294004
A proSpecTive, Randomized, controlled, single-blind, dose-finding, mUlti-Center, parallel group study of the safeTy and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in fibrin) versus local autograft for the treatment of patients undergoing single-level transforaminal lumbar intErbody fusion (the STRUCTURE study)
-
Protocol number: STUDY00001920
Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support
-
Protocol number: STUDY00002424
Investigating Exposure to Endocrine Disrupting Chemicals and Poor Sleep in Breast Cancer Survivors
-
Protocol number: STUDY00002550
Women s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
-
Protocol number: STUDY00002789
CONTIGO - Informing Latinas About HBOC Risk: a Randomized Controlled Trial
-
Protocol number: STUDY00003033-NCT04767373
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
-
Protocol number: STUDY00003073-NCT03820947
Medtronic VenaSeal Spectrum: Global, Post-Market Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
-
Protocol number: STUDY00003077-NCT04520776
A multicenter, prospective, randomized, clinical trial comparing the safety and effectiveness of the BAGUERA® C Cervical Disc Prosthesis to the Mobi-C® Cervical Disc for the treatment of patients with symptomatic cervical disc disease at a single level.
-
Protocol number: STUDY00003267
Families SHARE: Development and evaluation of a family health history education toolkit
-
Protocol number: STUDY00003415
Supporting Shared Decision Making in Metastatic Breast Cancer
-
Protocol number: STUDY00003424-NCT04564885
A MULTICENTER, PROSPECTIVE, RANDOMIZED, CLINICAL TRIAL COMPARING THE SAFETY AND EFFECTIVENESS OF THE BAGUERA ® C CERVICAL DISC PROSTHESIS TO THE MOBI - C ® CERVICAL DISC FOR THE TREATMENT OF PATIENTS WITH SYMPTOMATIC CERVICAL DISC DISEASE AT TWO CONTIGUOUS LEVELS
-
Protocol number: STUDY00003539
Improving Communication and Adherence in Black Breast Cancer Survivors
-
Protocol number: STUDY00003673
Developing a Multilevel Intervention for Screening Breast MRI
-
Protocol number: STUDY00003772
Understanding HPV Vaccination Behavior to Prevent Cancer
-
Protocol number: STUDY00004071
An advanced functional MRI study of frontostriatal injury in adults with HIV
-
Protocol number: STUDY00004298
Testing mHealth Delivery of Cognitive Behavioral Therapy for Insomnia to Breast Cancer Survivors
-
Protocol number: STUDY00004338
Cancer Center Organizational Assessment to Eliminate Outcome Disparities Among Childhood Cancer Survivors
-
Protocol number: STUDY00004397
Scaling Social Determinants of Health Screening, Social Support and Anti-Racism Training to Reduce Inequities in Minority Cancer Survivor Health and Wellbeing in Washington, DC
-
Protocol number: STUDY00004914
Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at MedStar Health: Pilot Study
-
Protocol number: STUDY00005081
Ecological Momentary Assessment of Quality of Life in Metastatic Breast Cancer
-
Protocol number: STUDY00005085
Examining the relationship between social and molecular risk factors for Black patients with endometrial cancer
-
Protocol number: STUDY00005170
A 104-week, multicenter, single-arm, long-term, phase 3 extension trial investigating the safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) completing the EASE SBS 2 trial
-
Protocol number: STUDY00005285
Development of an informational support intervention for patients with differentiated thyroid cancer after radioactive iodine treatment
-
Protocol number: STUDY00005586
Mixed-Methods Study of Financial Toxicity among Patients with Colorectal and Hematological Malignancies
-
Protocol number: SUMMIT-NCT03433274
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
-
Protocol number: SUN-PRO00038942
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
-
Protocol number: SURPLUS
Surgical Resection of Prosthetic Valve Leaflets Under Direct Vision (SURPLUS) Registry
-
Protocol number: SUSTAIN-4801
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight
-
Protocol number: TALAPRO-3-MWHC
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
Protocol number: TARGET-HCC-NCT02954094
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
-
Protocol number: TARGET-NASH-NCT02815891
A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis
-
Protocol number: TARGETHBV-NCT03692897
An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection
-
Protocol number: TBCRC-052
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
-
Protocol number: TBCRC037-NCT02206984
A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer
-
Protocol number: TBCRC045-NCT03414658
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab
-
Protocol number: TBCRC046-NCT04841148
A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer ( PALAVY )
-
Protocol number: TEASER-NCT02540109
Targeted Transcranial Electrotherapy to Accelerate Stroke Rehabilitation-Exploratory Trial on Aphasia
-
Protocol number: TEDREGISTRY-NCT04832087
Clinical use of Teduglutide in children with short bowel syndrome: a multi-center post-marketing evaluation
-
Protocol number: TH-IBA-CTR-1003
Theratechnologies Inc. - A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US)
-
Protocol number: THUMB-CMC
Prospective Longitudinal Study of Non-Operative and Operative Thumb CMC Arthritis Interventions
-
Protocol number: TJ003234COV201
A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)
-
Protocol number: TRAC-AFOUTCOMES
Tracking Results of Ablations to Combat AF Registry (Formerly the Maze IV Registry)
-
Protocol number: TRANSPORT2-NCT03826030
TRANScranial direct current stimulation for POst-stroke motor Recovery - a phase II sTudy (TRANSPORT 2)
-
Protocol number: TREATMS-NCT03500328
TRADITIONAL VERSUS EARLY AGGRESSIVE THERAPY FOR MULTIPLE SCLEROSIS (TREAT-MS) TRIAL
-
Protocol number: TREO-PAS
Post-Approval Study of the TREO Abdominal Stent- Graft System (P190015) in Patients with Infrarenal Abdominal Aortic and Aorto-iliac Aneurysms
-
Protocol number: TRILUMINATE-NCT03904147
Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal
-
Protocol number: TRIOMPHE-NCT04471909
A Multi-Arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS™ Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch
-
Protocol number: TRIUMPH-NCT99999999
Protocol I5Q-MC-B004: preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH)
-
Protocol number: TTI-622-01-NCT03530683
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma
-
Protocol number: TTNS-NCT04350359
Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
-
Protocol number: TUMORCOLLAGEN
Tumor Associated Collagen Signature in Hepatocellular Carcinoma
-
Protocol number: TVD-101-001H-NCT05440708
A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
-
Protocol number: TYR-219-01-NCT04474470
A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer
-
Protocol number: U31402-A-U103
A PHASE 1 OPEN-LABEL STUDY OF PATRITUMAB DERUXTECAN (U3-1402) IN COMBINATION WITH OSIMERTINIB IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NONSMALL CELL LUNG CANCER (NSCLC)
-
Protocol number: UCL-CHDI-1
HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington s disease
-
Protocol number: UCLAHCCRETRO
Multi-Institutional Validation of A Novel Prognostic Nomogram Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation
-
Protocol number: ULURU-BURN
Prospective Randomized Open Label Multicenter Phase IV Clinical Trial to Compare Transforming Powder Dressing (TPD) to Current Standard of Care (SOC) Dressing Therapies in Acute Partial Thickness Burn Wounds
-
Protocol number: URCC-21038-DIRECT-NCT05364086
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study (DiRECT)
-
Protocol number: VERIFY-NCT05338697
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials (VERIFY)
-
Protocol number: VERILY-NCT04905459
A multicenter study to evaluate the performance of Automated Retinal Disease Assessment software for the detection of more than mild Diabetic Retinopathy (ARDA mtmDR study)
-
Protocol number: VERISMO
AN OBSERVATIONAL STUDY OF OCRELIZUMABTREATED PATIENTS WITH MULTIPLE SCLEROSIS TO DETERMINE THE INCIDENCE AND MORTALITY RATES OF BREAST CANCER AND ALL MALIGNANCIES (VERISMO STUDY)
-
Protocol number: VIB0551-P3-S1
A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS
-
Protocol number: VICTORION-2P-NCT05030428
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
-
Protocol number: VICTORION-GSH
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (≥70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE)
-
Protocol number: VICTORION-INCEPTION
A randomized, controlled, multicenter, open-label trial comparing a hospital post-discharge care pathway involving aggressive LDL-C management that includes inclisiran with usual care versus usual care alone in patients with a recent acute coronary syndrome(VICTORION-INCEPTION)
-
Protocol number: VICTORION-INITIATE
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (≥70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE)
-
Protocol number: VIIV
A multi- site observational study to assess safety and effectiveness of prenatal exposure to Dolutegravir in HIV positive pregnant women
-
Protocol number: VISUAL-HEARTFAIL
Patient Visualization of Personalized Cardiac Imaging to Improve Health Literacy and Medication Adherence in Patients with Heart Failure
-
Protocol number: VLX-601
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)
-
Protocol number: VS-6766-203
A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
-
Protocol number: VS-6766-NCT04620330
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)
-
Protocol number: VULVIE
A randomized controlled trial of Vulvar fractionated CO2-Laser therapy with and without concomitant topical clobetasol propionate 0.05% ointment for treatment of Vulvar lichen sclerosus
-
Protocol number: WA42293
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
-
Protocol number: WATS-NCT02988934
The WATS3-D (Wide Area Transepithelial Sample Biopsy with 3-Dimensional Computer-Assisted Analysis) U.S. Registry
-
Protocol number: WELLDOC
Safety of a Real-time Continuous Glucose Monitor-based Insulin Bolus Calculator: The CGM-IBC; Study B
-
Protocol number: WF-1805CD-HN-STAR-NCT04208490
Implementation and Effectiveness Trial of HN-STAR
-
Protocol number: WF-1806-NCT03998202
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer (M&M) (NCORP)
-
Protocol number: WHITEMATTER-NCT03366129
The Natural History of Blood-Brain Barrier Disruption in Stroke Patients with White Matter Hyperintensities (A Cohort Study)
-
Protocol number: WN42171
AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE
-
Protocol number: WN43194
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
-
Protocol number: Z11102
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
-
Protocol number: ZYGOOD-NCT04000867
Treatment for Foot Pain Caused by Diabetic Neuropathy Using Recurrent TransCutaneous Magnetic Stimulation (TCMS)
All clinical trials
Our trials are carefully planned research studies that have led to important discoveries such as new drugs, procedures, and diagnostic approaches that make our lives better.
Volunteering in our trial offers potential benefits, including:
-
The opportunity to become involved in the testing of a new drug that may have potential to improve your condition
-
Close contact with the study team for management of your disease
-
Contributing to medical science, which may help others now and in the future
Frequently asked questions
-
Q: Why volunteer?
A: Does volunteering for a clinical trial make sense for you? The following information will help you to decide.
-
Q: What are clinical trials and why are they important?
A: Clinical trials are carefully planned research studies that have led to important discoveries such as new drugs, devices, procedures, biologics, and diagnostic approaches. These new discoveries make our lives better such as new medicines to treat cancer, diabetes, and other diseases. Some other words for clinical trials are research, survey, or experiment.
Know what you are getting into and don’t be afraid to ask questions. A clinical trial may or may not help you personally. The results from the study could help others who have a health problem. Taking part in research is voluntary. It is your decision!
-
Q: Why do we need clinical trials?
A: A series of clinical trials for each possible treatment must be done before the Food and Drug Administration (FDA) will approve a drug, procedure, or device. Many of the trials done at MedStar Health Research Institute are trials testing possible drugs or devices. A drug must be shown to be safe and useful for public use before the FDA can approve it.
From the lab bench to the drug store, developing a new drug is a long and expensive process. It is estimated to take about 10 years and $800 million to bring one new drug to market (R & D Directions, January 2002).
-
Q: Are clinical trials safe?
A: Protections have been put in place to safeguard your rights, safety, and privacy in research. Many layers of oversight include an institutional review board (ethical review board), the Food and Drug Administration (FDA), and periodic monitoring of study data by independent experts, patient advocates, community advisory board members, and community partners.
-
Screening trials test the best way to detect certain diseases or health conditions
-
Diagnostic trials determine better tests or procedures for diagnosing a particular disease or condition
-
Treatment trials test new treatments, new combinations of drugs, or new approaches to surgery
-
Quality of life trials explore and measure ways to improve the comfort and quality of life of people with a chronic illness
-
-
Q: Who can participate in a clinical trial?
A: People with the condition being studied or healthy people can volunteer to take part in a clinical trial. Each study has specific entry requirements such as age or a medical condition necessary for participation.
The doctor in charge of the study must review the volunteers' medical history to determine if he/she is eligible to participate based on strict study conditions called entry criteria.
-
Q: Who is in charge of a clinical trial?
A: A medical doctor is usually responsible for carrying out the study according to the study protocol. Before a clinical trial can begin to enroll volunteers, an Institutional Review Board (IRB) must approve it. The IRB is a committee made up of healthcare experts that review each study to protect patient rights and ensure the safety of research volunteers. The IRB also ensures the research is scientifically sound and is involved in the review of safety issues throughout the study.
-
Q: What is informed consent?
A: One of the documents the IRB must review and approve is called an Informed Consent Form. This is provided to volunteers who are interested in participating in a clinical trial program. The informed consent includes everything a volunteer needs to know about the study so that he/she can make an informed decision as to whether or not to participate. The process allows volunteers to ask questions. Volunteers are encouraged to take their time in making a decision before signing the consent and joining the study. You and your family should feel completely comfortable with your decision to participate before you sign the consent.
-
Q: What are the benefits to being in a clinical trial?
A: Once enrolled in a clinical trial, many volunteers find there are a number of potential benefits to participation. These can include:
-
The opportunity to become involved in the testing of a new drug that may have potential to improve your condition.
-
Close contact with the study team for management of your disease.
-
Contributing to medical science, which may help others now and in the future.
However, volunteers understand that there may not be any benefit to participating in a study.
-
-
Q: Why do we need diversity in a research?
A: Race, ethnicity, age, and other factors can affect how people respond to medicine.
-
Q: Why do many still feel uneasy about being part of a clinical trial?
A: The Tuskegee Syphilis Study and the cancer cells taken from Henrietta Lacks without her knowledge are two reasons for the continued distrust with the African American community. Today, there is low participation in clinical trials from African Americans. We may not know if certain treatments will be effective in this population.
-
Q: Will my health insurance pay for a clinical trial?
A: Federal law requires insurance companies to cover routine costs, which are things you need regardless of a clinical trial. If the study sponsor requires extra testing, they will typically cover the cost.
-
Q: Can I drop out of a clinical trial and still receive quality care?
A: You are in control. If you decide you do not want to participate anymore, you can withdraw at any time. You will receive the same high-quality care at MedStar Health. Your clinical team may ask to continue monitoring you for a period of time to assess effects of the treatment you have already received.
-
Q: Are clinical trials considered a last-ditch effort for patients?
A: Not true at all! Clinical trials allow access to treatments that are up and coming but not yet available to the general population.
-
Q: Interested in participating in a clinical trial by MedStar Health?
A: Email JoinResearch@MedStar.net or call 833-998-0900 (toll-free) to learn more and ask about our open studies.